Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AACR: Three Promising Anticancers From Loxo Oncology, Ignyta And BeiGene

This article was originally published in Scrip

Executive Summary

Investigational anticancer drugs aimed at new potential targets, particularly those involving genetic abnormalities that can be identified for diagnostic purposes, were the focus of presentations on their safety and efficacy in Phase I studies at this year's American Association for Cancer Research (AACR) meeting, being held in New Orleans on Apr. 16-20.

Advertisement

Related Content

Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants

Topics

Advertisement
UsernamePublicRestriction

Register

SC064989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel